BioCentury
ARTICLE | Company News

EntreMed cancer, autoimmune news

December 22, 2008 8:00 AM UTC

EntreMed restructured and reduced headcount by 30 (59%) to 21 to lower costs. The company will focus on its ENMD-2076, a dual-acting aurora A and tyrosine kinase inhibitor in Phase I testing to treat solid tumors and multiple myeloma (MM). EntreMed will suspend its remaining programs, including MKC-1, an oral cell cycle inhibitor in Phase II testing for cancer; ENMD-1198, a second-generation 2-methoxyestradiol ( 2ME2) analog in Phase I for cancer; and Panzem NCD 2-methoxyestradiol, a naturally occurring estrogen metabolite in preclinical testing for rheumatoid arthritis (RA). Ongoing trials will not be affected. ...